Using charged lipid nanoparticles to improve inhaled mRNA vaccines for mucous membranes

Inhaled charge-assisted stabilization lipid nanoparticles (CAS-LNP) show enhanced stability during nebulization, enabling efficient pulmonary mRNA delivery.

• CAS-LNPs maintain stability during nebulization, overcoming challenges associated with traditional lipid nanoparticles.
• Efficient delivery of mRNA occurs in mice, dogs, and pigs, suggesting broad applicability across species.
• Inhaled CAS-LNP effectively transfects dendritic cells, leading to strong immune responses both locally and systemically.
• The CAS-LNP demonstrates potential as a vaccine against the SARS-CoV-2 Omicron variant and as a cancer vaccine targeting lung metastasis.
• Design principles for nebulized lipid nanoparticles are outlined, which could facilitate future inhaled mRNA therapeutics.

Simplified